Sponsored symposium

A prIME Oncology activity supported by Alexion Pharmaceuticals

Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) and atypical HUS (aHUS) are two rare, life-threatening disorders characterized by systemic thrombotic microangiopathy (TMA) due to uncontrolled complement activation.  These complement-mediated TMAs result in hemolytic anemia, thrombocytopenia, severe kidney damage, and multi-organ failure. Though these TMAs share a similar presentation, they differ in etiology; STEC-HUS emerges from infection with enteropathogenic Eschericia coli while aHUS arises from genetic defects in the complement regulatory system. The lunchtime satellite symposium STEC-HUS and aHUS: Complement-Mediated Thrombotic Microangiopathies will address the similarities and differences in the pathogenesis and diagnosis of these two unique TMAs and discuss novel complement-targeting therapy that has become a successful management option for patients with aHUS.

Tuesday, 8 May 12:30 - 13:30 hrs
Location: E102

Click here for more information